**Letter**

**Title: concisely convey the main topic(s) of the research**

[***Suggestions: No more than 16 words.*** ***No abbreviations*** ***except for standardized ones e.g., DNA, RNA, etc.***]

**Forename Surname1, Forename Surname1,2, Forename Surname3**

*1Department, Institution, City Postcode, Country.*

*2Department, Institution, City, State Postcode, Country.*

*3Department, Institution, City Postcode, Province, Country.*

**Correspondence to:** Prof./Dr. Forename Surname, Department, Institution, Detailed Address, City Postcode, Country. E-mail: xxxx@xxxx.xxx

Received: date month year

*[*e.g.,1 Jan 2018*]*

**How to Use This Template**

***This template shows the manuscript structure that can be used in a letter: Main Text, Declarations and References. Please note that each part has a corresponding style, which authors should follow. “Please note that the fonts in gray show writing requirements”. For any questions, you may contact the editorial office.***

**Abstract (optional)**

[***Suggestions: No more than 250 words. No citations. Define abbreviations at their first mention.***]

Abstract is a brief summary of an article, which helps the readers quickly ascertain the paper's main content. In this part, authors may mention writing purpose, experimental methods, results and their significance in this research field, *etc*.

**Keywords (optional):** Tumor microenvironments, *Foxp3,* transforming growth factor-β1, *Helicobacter pylori,* Notch, DNA, high performance liquid chromatography

***[Please suggest 3-8 keywords which can be used for describing the content of the manuscript and will enable the full text of the manuscript to be searchable online]***

**LEVEL 1 HEADING**

*[*e.g.,**MAIN TEXT***]*

In this section, authors should describe the main text of the manuscript in detail. If necessary, we suggest that authors may set headings (level 1 heading, level 2 heading, level 3 heading, *etc.*) to separate different cases or situations.

**Level 2 heading**

*[*e.g.,**Statistical analyses***]*

*Level 3 heading*

*[*e.g., *Data distributions, outliers and linear regression]*

***Tips:***

* ***All drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration, should be identified precisely.***

**Table 1** (other forms: Tables 1 and 2; Tables 1-3),**Equation (1)** [other forms: Equations (2) and (3); Equations (4-6)] and **Figure 1** (other forms: Figure 1A and B; Figure 2A-C; Figures 1 and 2A; Figures 1, 2A and 3-5) show the examples of diagrams. All the tables, equations and figures should be cited in sequence in the main content near to the first time they appear. For supplementary material, authors may cite table, equation and figure like **Supplementary Table 1**, **Supplementary Equation (1)** and **Supplementary Figure 1**. For details, you may refer to **[Supplementary material template](http://www.oaepublish.com/files/tpl/jcmt/Template_for_Supplementary_Material_jcmt.docx)**.

***Tips:***

* ***Results should be presented in a logical sequence;***
* ***Avoid redundant explanations to all the data from the tables or illustrations.***

|  |  |
| --- | --- |
| **A** | 图二**B** |
| **C** |

**Figure 1.** We present examples of electron micrograph, non-editable and editable images in Figure 1A-C. A: description of what the Figure 1A is; B: description of what the Figure 1B is; C: description of what the Figure 1C is. DC: dendritic cells; MHC: major histocompatibility complex; NK: natural killers; WS: Withania somnifera. This figure is quoted with permission from XX *et al*.[2]

***Figure notes:***

* ***It’s highly recommended that authors provide figures in format of TIFF, PSD, AI, or JPEG, with resolution 300-600 dpi.***
* ***Figures should be clearly displayed. Non-English words should be avoided.***
* ***If there is a copyright issue, authors should*** ***obtain copyright permission for using it. For more details,*** ***see [Author Statement](http://jcmtjournal.com/pages/view/author_statement).***
* ***Authors should pay attention to the protection of patients’ rights, such as privacy and portrait, and obtain signed patient consent from authors before using any personal information of patients. The patient’s portrait with full characters and his/her real name is not allowed for use.***

|  |  |
| --- | --- |
|  | (1) |

***Equation note:***

* ***Equations should be provided in editable form (image file format is not allowed).***

**Table 1. This is a table caption. A summary description of this table should be written here**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Authors** | **Regimen** | ***n*** | **Age (year)** | **CR (%)** | **2-year (3-year) EFS/PFS (%)** | **2-year (3-year) OS (%)** |
| Our current study | CHOPCVP | 25167 | 17-8245-87 | 69.829.9\* | 55.3 (46.0)18.0 (12.0)\* | 58.0 (52.0)25.0 (19.0)\* |
| Khaled *et al.*[1] | CHOP | 40 | 19-75 | 67 | 54 (54) | 82 (71) |
| Burton *et al.*[2] | CHOPCIOP | 105106 | 22-6625-67 | 7052 | 4-year PFS: 564-year PFS: 40\* | 4-year OS: 654-year OS: 56# |

This part is footer. \**P* < 0.05, #*P* ≥ 0.05. EFS: event-free survival; PFS: progression-free survival; OS: overall survival; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP: cyclophosphamide, vincristine, and prednisone; CIOP: cyclophosphamide, idarubicin, vincristine, and prednisone; CR: complete response. This table is cited with permission from Li *et al*.[1] published in xxx

***Table notes:***

* ***Tables should be provided in editable form (image file format is not allowed).***
* ***Non-English words should be avoided.***

**DECLARATIONS**

**Acknowledgments (optional)**

If there are contributions that need acknowledging but do not justify authorship, such as general support by a departmental chair, technical help, *etc.*, please state in this part; if there is not, this subsection could be deleted.

**Authors’ contributions**

*Single author:*

*Author (Surname + abbreviation of Forename)* *solely responsible for the paper.*

*Two or more authors*:

*Design: Author 1 (Surname + abbreviation of Forename)*

*Literature research: Author 2 (Surname + abbreviation of Forename), Author 3 (…)*

*Data analysis: Author 3 (…)*

*Manuscript writing: …*

*Manuscript editing: …*

*Manuscript revision: …*

*…*

**Financial support and sponsorship**

*If there are grants*

*This work was supported by Grant name XX (No. XXX; No. XXX)...*

*If there is no grant:*

*None.*

**Conflicts of interest**

If there are any potential conflicts of interest about the manuscript version, authorship, or others, please declare here.

If not, please write as “*There are no conflicts of interest*”.

**Patient consent**

Not applicable.

**Ethics approval**

Not applicable.

**Copyright**

© The Author(s) 2018.

**REFERENCES**

Authors should cite references in sequence throughout the manuscript and indicate them in a superscript square bracket with one citation number[3], two separate citation numbers[4,5] or several consecutive citation numbers[6-9].

* ***We suggest that authors should cite appropriate and latest references be within recent 5 years.***
* ***Each reference should have a corresponding DOI number/website link.***
* ***All authors’ names should be listed in the references.***
* ***The names of journals should be abbreviated according to the style used in Index Medicus (<http://www2.bg.am.poznan.pl/czasopisma/medicus.php?lang=eng>).***

Examples of references are shown below:

***Standard journal articles (list all authors)***

1. Parija SC, Ravinder PT, Shariff M. Detection of hydatid antigen in the fluid samples from hydatid cysts by co-agglutination. *Trans R Soc Trop Med Hyg* 1996;90:255-6.

***Standard journal articles (Both personal authors and organization as author)***

1. Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. *J Urol* 2003;169:2257-61.

***Standard journal articles not in English (the title should be translated into English, and clarify the original language in the bracket)***

1. Zhang X, Xiong H, Ji TY, Zhang YH, Wang Y. Case report of anti-N-methyl-D-aspartate receptor encephalitis in child. *J Appl Clin Pediatr* 2012;27:1903-7. (in Chinese)

***Standard journal articles ahead of print (DOI number should be given)***

1. [Almonroeder TG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Almonroeder%20TG%5BAuthor%5D&cauthor=true&cauthor_uid=29320946), [Kernozek T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kernozek%20T%5BAuthor%5D&cauthor=true&cauthor_uid=29320946), [Cobb S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cobb%20S%5BAuthor%5D&cauthor=true&cauthor_uid=29320946), [Slavens B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Slavens%20B%5BAuthor%5D&cauthor=true&cauthor_uid=29320946), [Wang J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29320946), [Huddleston W](https://www.ncbi.nlm.nih.gov/pubmed/?term=Huddleston%20W%5BAuthor%5D&cauthor=true&cauthor_uid=29320946). Cognitive demands influence lower extremity mechanics during a drop vertical jump task in female athletes. *[J Orthop Sports Phys Ther](https://www.ncbi.nlm.nih.gov/pubmed/29320946%22%20%5Co%20%22The%20Journal%20of%20orthopaedic%20and%20sports%20physical%20therapy.)* 2018; doi: 10.2519/jospt.2018.7739.

***Books***

1. Sherlock S, Dooley J. Diseases of the liver and billiary system. 9th ed. Oxford: Blackwell Sci Pub; 1993. p. 258-96.

***Chapter in a book***

1. Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.

***Online resource***

1. FDA News Release. FDA approval brings first gene therapy to the United States. Available from: <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm>. [Last accessed on 30 Oct 2017]

***Conference proceedings***

1. Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.

***Conference paper***

1. Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182-91.

***For other types of references please refer to ICMJE Guidelines ([https://www.nlm.nih.gov/bsd/uniform\_requirements.html)](https://www.nlm.nih.gov/bsd/uniform_requirements.html).***